MINNEAPOLIS (June 26, 2012) – DaVita Clinical Research® (DCR®), a provider of clinical research services focused on kidney research as well as a multitude of specialty therapeutic populations, has hired four individuals to ignite the expansion of DCR at its latest clinical research facility in Denver, Colo., scheduled to open this month. The new team members are: Dr. Christopher Galloway, Medical Director; Chad Jaeger, Senior Director of Clinical Operations; Amy Denvir, Director of Operations-Denver; and Michael Kreuter, Director of Data Management.
With more than 12 years of medical practice, including six years within emergency and critical care, Galloway brings great industry experience in his new role as medical director for DCR. He served as an attending physician for Capitol Emergency Associates in Austin, Texas, Front Range Emergency Associates in Colorado Springs, Colo., and the University of Tennessee in Knoxville.
Jaeger’s involvement within the early clinical research industry spans the past 16 years in both clinical and commercial operations and includes former employers Harris Laboratories, MDS Pharma Services and Radiant Research. His last position prior to joining DCR was senior account executive for Covance’s early clinical pharmacology units. A graduate of the University of Nebraska-Lincoln, Jaeger is a member of the American Society for Clinical Pharmacology and Therapeutics (ASCPT).
As the Director of Operations, Denvir will utilize more than 20 years of early phase CRO industry experience to successfully launch the new Denver facility and ensure Good Clinical Practice (GCP) is maintained. Denvir formerly worked for Metroplex Clinical Research Center, Covance, Radiant Research and MDS Pharma Services in a variety of operational leadership roles.
Kreuter has held various senior level data management director positions for the past 16 years at several organizations including Sanofi Pasteur in Swiftwater, Penn., M3 Clinical Research in Hinckley, Ohio, and SDI in Plymouth Meeting, Penn. Kreuter received his master’s degree in healthcare administration from Almeda University and is also an active member in numerous industry organizations.
“These individuals are leaders in their fields and bring exponential experience to our expanded clinical research capabilities at our new facility,” stated Amy Young, DCR vice president of clinical services. “We’re proud to bring in such qualified talent to lead our new facility as we continue to expand DCR and fulfill our mission to advance the knowledge and practice of kidney care.”
DCR’s new facility encompasses 35,000 square feet and will be physically connected to St. Anthony Hospital in Lakewood, Colo. The 80-bed facility will create more than 50 specialized research jobs and will increase DCR’s physical capacity from 42 to 122 beds in North America. The facility will support high-risk studies and will have an expanded ability to support both patient and healthy volunteer Phase I clinical studies.
“These significant investments in talent signify our commitment to be a leader in the early clinical research space,” said Kevin Goudreau, DCR vice president of commercial development. “DaVita Clinical Research will continue to explore opportunities to both expand our patient-driven leadership position and diversify our ability to conduct critical research in healthy normal volunteers.”
DaVita, DaVita Clinical Research and DCR are trademarks or registered trademarks of DaVita Inc. All other trademarks are the property of their respective owners.
About DaVita Clinical Research (DCR)
DaVita Clinical Research (DCR), a wholly owned subsidiary of DaVita Inc., is committed to advancing the knowledge and practice of kidney care. DCR brings knowledge, skill and expertise to pharmaceutical research, facilitating the success of its clients’ clinical trials. DCR’s clinical expertise spans the lifecycle of drug development. DCR’s Early Clinical Research unit (Phase I-IIa) and Clinical Development network of physicians and investigative sites, data research, Health Economics & Outcomes Research, Central Laboratory, Advisory Committee prep, and Medical Communications are focused on providing world-class clinical research in both complex/specialty populations and therapeutic areas, and especially in CKD and ESRD populations. To learn more about DCR, visit preview.davitaclinicalresearch.com.
DaVita Inc., a Fortune 500® company, is a leading provider of kidney care in the United States, delivering dialysis services to patients with chronic kidney failure and end stage renal disease. DaVita strives to improve patients’ quality of life by innovating clinical care, and by offering integrated treatment plans, personalized care teams and convenient health-management services. As of March 31, 2012, DaVita operated or provided administrative services at 1,841 outpatient dialysis centers located in the United States serving approximately 145,000 patients. The company also operated 15 outpatient dialysis centers in three countries outside the United States. DaVita supports numerous programs dedicated to creating positive, sustainable change in communities around the world. The company’s leadership development initiatives and social responsibility efforts have been recognized by Fortune, Modern Healthcare, Newsweek and WorldBlu. For more information, please visit www.davita.com.